Ozempic could be the next target of Medicare drug price negotiations – here’s why
[ad_1] A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line in the price negotiations between manufacturers…